Articles
FMA UK statement on recent government change in policy regarding Cannabis medicines.
- Details
- Category: General Information
- Published on Wednesday, 21 November 2018 10:24
- Hits: 4042
Fibromyalgia Action UK firmly believes that clinical practice must be based on good quality evidence. As a charity responsible for advocating on behalf of people with fibromyalgia experiencing chronic pain, we support Pain UK’s recent statement, calling for further investment into research in this area, in order to ensure that we have the clinical evidence required to help people with chronic pain conditions like fibromyalgia.
We have heard from many people with fibromyalgia who reacted positively to the Government’s announcement in September 2018 about Cannabis-based products for medicinal use. There were expressions of hope that people may be able to legally access a treatment that they were currently benefiting from. We also recognise that the current draft scope guideline formulated by the National Institute for Health and Care Excellence (NICE) on Cannabis-based products for medicinal use does not include the Cannabidiol (CBD) food supplement area, which we anecdotally know that many people in the UK are using in hope of helping to manage their chronic pain. Fibromyalgia Action UK have registered as a stakeholder with NICE when developing this guidelines, to ensure that the voice of people with fibromyalgia is recognised.
Rather than bringing clarity and hope that may have been expected, the recent rescheduling of legislation by the Government to allow for the medicinal use of cannabis-based products, prescribed by specialist doctors listed on the General Medical Council’s (GMC) specialist register, has led to people with chronic pain feeling more isolated and confused. We support Pain UK’s urgent request of Government and all agencies providing healthcare to consult with stakeholders to address this confusion in a proactive and timely manner.